AllSci News
Thryv expands SGK1 platform into neurodegeneration with Spanish academic license
Montréal-based Thryv Therapeutics Inc. has licensed an exclusive, worldwide patent and know-how rights to a structurally distinct class of SGK1 inhibitors...
AbbVie closes USD 10.9b Apogee purchase for IL-13 zumilokibart
AbbVie (NYSE: ABBV) completed its acquisition of Apogee Therapeutics on September 3, 2026, paying USD 135.11 per share in cash for a total equity value of...
Pfizer hands former Seagen ADC to Medicus in USD 1b-plus deal
Medicus Pharma Ltd. (Nasdaq: MDCX) has licensed worldwide rights to Pfizer's PF-08046031 (CD228V), an early clinical-stage antibody-drug conjugate (ADC)...
China approves two homegrown long-acting RSV antibodies for infants
China's National Medical Products Administration (NMPA) has approved two domestically developed long-acting monoclonal antibodies for the prevention of...
AbbVie’s monthly BCMAxCD3 bispecific clears Phase III hurdle
AbbVie (NYSE: ABBV) has reported that etentamig, its investigational BCMA × CD3 bispecific T-cell engager (TCE), met both dual primary endpoints in the...
Hengrui files Kailera-partnered oral GLP-1 for China approval in obesity and diabetes
China's drug regulator has accepted a marketing authorization application for HRS-7535 tablets, an oral small-molecule glucagon-like peptide-1 receptor...
ARPA-H backs USD 125m push for distributed RNA manufacturing
The Advanced Research Projects Agency for Health (ARPA-H) has selected five teams to receive contract awards totaling up to USD 125 million under its...
Servier secures option to Luxna's XNA chemistry platform for neurological ASO programs
Servier has expanded its research collaboration focused on Luxna Biotech Co., Ltd's XNAs Technology platform. The France-based pharmaceutical giant has...
Kali, Sanofi's tri-specific T-cell engager cleared for US study in rheumatoid arthritis
California-based Kali Therapeutics announced US FDA clearance of an investigational new drug (IND) application for KT501, a trispecific B-cell–depleting...
France clears Sensorion's gene therapy SENS-601 into human testing for GJB2 hearing loss
France's drug regulator has cleared Sensorion to begin human testing of SENS-601, its adeno-associated virus (AAV)-based gene therapy for GJB2-related...
Menarini puts up EUR 726M for Euro rights to Gan & Lee’s biweekly GLP-1
China-based Gan & Lee Pharmaceuticals (SSE: 603087) has licensed European rights to bofanglutide (GZR18), its biweekly glucagon-like peptide-1 receptor...
NEJM publishes daraxonrasib NSCLC data supporting Phase III program
Revolution Medicines (Nasdaq: RVMD) has published updated Phase I/II data in the New England Journal of Medicine showing antitumor activity for daraxonrasib...
NMPA accepts Hansoh’s B7-H3 ADC HS-20093 in post-platinum SCLC
China's National Medical Products Administration (NMPA) has accepted a biologics license application from Hansoh Pharmaceutical Group Company Limited (HKEX:...
ARPA-H backs Waterfall Scientific-led mRNA manufacturing platform with up to USD 54.5m
Worcester, Massachusetts-based Waterfall Scientific has been selected by the Advanced Research Projects Agency for Health (ARPA-H) to lead a six-company...
Akeso's ivonescimab beats Keytruda on overall survival in advanced NSCLC
Akeso's ivonescimab has now demonstrated a statistically significant overall survival benefit versus Merck's Keytruda (pembrolizumab) monotherapy in...
The AllSci Brief
Free, systematic R&D and deal news. Daily.